Related Experiment Video
Updated: Jun 17, 2025
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.4K
Durvalumab-Induced Triple-M Syndrome
Femi Williams Adeoye1, Nida Jaffar2, Sanggeeta Surandran3
1Southend University Hospital, Southend-on-Sea, United Kingdom.
European Journal of Case Reports in Internal Medicine
|August 12, 2024
Summary
This case study highlights a rare instance of triple-M syndrome, a potentially life-threatening side effect of immunotherapy, specifically durvalumab. Early recognition and multidisciplinary care are crucial for managing this complex immune-related adverse event.
Area of Science:
- Oncology
- Immunology
- Neurology
- Cardiology
Background:
- Immunotherapy has transformed cancer treatment but can cause immune-related adverse effects.
- Immune checkpoint inhibitors (ICIs) like durvalumab are effective but carry risks.
- Adverse effects of ICIs necessitate careful monitoring and management.
Purpose of the Study:
- To report a rare case of durvalumab-induced triple-M syndrome.
- To increase awareness of this potentially life-threatening ICI side effect.
- To emphasize the importance of early recognition and multidisciplinary management.
Main Methods:
- Case report of a 69-year-old woman with stage III lung adenocarcinoma.
- Detailed clinical presentation, diagnostic findings, and treatment course.
- Review of literature on ICI-induced myocarditis-myositis-myasthenia complex.
Main Results:
- The patient developed symptoms of myositis, myasthenia, and myocarditis (triple-M syndrome) during durvalumab therapy.
- Diagnosis confirmed by clinicopathological features and electrocardiogram findings.
- Treatment with high-dose steroids and intravenous immunoglobulin led to improvement.
Conclusions:
- Triple-M syndrome is a rare but serious adverse effect of ICIs, including durvalumab.
- Early diagnosis and prompt, multidisciplinary intervention are vital for patient outcomes.
- This case underscores the need for vigilance regarding ICI-induced autoimmune syndromes.
